Jeffrey Ubben

A little more than three years after ValueAct Capital CEO Jeffrey Ubben disclosed the fund’s massive $2 billion stake in Microsoft Corporation (NASDAQ: MSFT), the stock has nearly doubled in price. The day before Ubben discussed the position at an investor conference in April of 2013,...

There has been a heated debate on Wall Street as to whether activist investors are beneficial to both shareholders and companies. Over the past few years, activist investing has taken off, with several big name players pushing for change at some of the world's largest companies. While some argue...

Activist investor Bill Ackman manages Pershing Square Capital Management, a successful hedge fund firm with a concentrated equity portfolio worth $14.44 billion as of the end of the second quarter of the year. The equity portfolio comprises only seven stocks; 44 percent of its total assets are...

Bill Ackman, founder and CEO of hedge fund Pershing Square Capital Management, acquired a $3.3 billion stake in Valeant Pharmaceuticals Intl Inc (NYSE: VRX), a source familiar with the matter told Reuters on Monday. With this stake, the fund holds about 5 percent of the company's shares...

Activist hedge fund ValueAct Capital Management, run by Jeffrey Ubben, plans to raise up to $1.5 billion in new funds. After roughly three years without bringing in new capital, the fund could use the proceeds to either increase the size of preexisting bets or open new positions. One thing is...